DBA Dissertation.pdf

Stem cell tourism has become a dynamic and transformative aspect of global healthcare, providing new and innovative treatments for chronic and previously untreatable conditions. The present dissertation examines the opportunities, challenges and prospects of stem cell tourism with a focus on global markets and the Asia-Pacific region. It utilized a qualitative approach to research wherein semi-structured interviews with the main stakeholders, which include healthcare providers, policymakers and patients were conducted and combined with the review of the secondary data along with thematic evaluation to provide an all-rounded view of the industry. Findings of the research point out significant disparities in regulatory frameworks, ethical concerns and quality standards among different regions as well as market leaders were from Asia-Pacific nations such as Japan, Thailand and Malaysia. Competitive pricing, high standard medical infrastructure and innovative processes are being implemented by these nations to attract more international patients, but at the same time, the risk factors for the patients and credibility of the industry as a whole pose a severe risk due to proliferating unregulated clinics and unethical practices. This study calls for international harmonization in regulations, high-quality assurance measures and ethics to make stem cell tourism sustainable. Future trends of the industry will include personalized medicine, 3D bioprinting and digital transformation. These future trends will offer challenges and opportunities in equal measure. Recommendations emphasize informed consent, education for patients and collaboration between stakeholders on safety, efficacy and ethical responsibility. This research contributes to the understanding of stem cell tourism's global impact, offering actionable insights for policymakers, healthcare providers and researchers. Addressing the regulatory gaps and ethical dilemmas can unlock the full potential of the industry in revolutionizing healthcare while safeguarding patient welfare.